Agentase
Founded Year
1998Stage
Acquired - II | AcquiredTotal Raised
$4.99MAbout Agentase
Agentase develops biocatalyst preparations. The company works with a variety of federal agencies and corporate clients to develop enzyme-based systems tailored to specific performance criteria. Its technology addresses the perceived limitations of enzyme catalysis such as short catalytic lifetimes that restrict product shelf life and reduce catalyst productivity, acute environmental sensitivity that limits the range of acceptable conditions for catalysis, and vulnerability to thermal denaturation by developing application vehicles capable of protecting enzymes from adverse environments while enhancing their utility in a specific application.
Missing: Agentase's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Agentase's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Agentase Patents
Agentase has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/12/2013 | 9/27/2016 | Ointments, Microbiology, Infectious diseases, Bacteria, Epidemiology | Grant |
Application Date | 6/12/2013 |
|---|---|
Grant Date | 9/27/2016 |
Title | |
Related Topics | Ointments, Microbiology, Infectious diseases, Bacteria, Epidemiology |
Status | Grant |
Latest Agentase News
Sep 30, 2020
by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login by Gerrard Cowan US Army units will soon begin receiving a chemical detection system designed to simplify and enhance neurotoxin detection, with plans to expand the technology’s use cases in the coming years. The Contamination Indicator/Decontamination Assurance System (CIDAS) was developed with initial funding from the Army Research Office (ARO), part of the US Army Combat Capabilities Development Command’s Army Research Laboratory (ARL). CIDAS is the FLIR Agentase C2 Disclosure Spray, and the system initially stemmed from funded efforts between ARL and researchers at the University of Pittsburgh, with the latter founding a company – Agentase, LLC – in 1999 to further pursue the work. This company was acquired by FLIR Systems in 2010. The system is designed to catch particular classes of neurotoxins, such as nerve agents that are extremely toxic to humans. It can detect chemical weapons accurately at low concentration levels, according to ARO. The system uses enzymes – which ARO defines as “complex proteins naturally produced by living organisms that act as a catalyst for specific biochemical reactions” – to quickly produce colour-based reactions with chemical warfare agents. When they are applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. When CIDAS is applied to a surface in liquid form as a spray, a colour change identifies the precise location of contamination by a chemical warfare agent. (ARO) The rapid colour change can be used to expedite the decontamination process by enabling up-front triage of contaminated equipment, as well as post-decontamination assurance that the threat has been successfully detoxified, said Jeremy Walker, director of science and technology for detection systems at FLIR. Already a Janes subscriber? Read the full article via the Client Login
Agentase Frequently Asked Questions (FAQ)
When was Agentase founded?
Agentase was founded in 1998.
Where is Agentase's headquarters?
Agentase's headquarters is located at 2240 William Pitt Way, Pittsburgh.
What is Agentase's latest funding round?
Agentase's latest funding round is Acquired - II.
How much did Agentase raise?
Agentase raised a total of $4.99M.
Who are the investors of Agentase?
Investors of Agentase include FLIR Systems, ICx Technologies, U.S. Department of Defense, National Science Foundation, U.S. Army and 6 more.
Who are Agentase's competitors?
Competitors of Agentase include Brainsgate, Erydel, Corium International, Savara, Vapore and 12 more.
Compare Agentase to Competitors
Nanomi develops membrane emulsification process technology and equipment for:nn * monodisperse emulsionsn * monodisperse double emulsionsn * monodisperse microspheres (e.g. drug delivery systems)n * monodisperse microbubblesnnHeart of the company's technology is a emulsification membrane, fabricated with microscopic precision by proven photolithographic processes from the semiconductor industry. Nanomi follow a partnering strategy where the combination of the company's technology and their application formulation will enable users to provide their customers with new high value-added products.n
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products.
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
Berkeley Advanced Biomaterials Inc. (BAB) specializes in developing and manufacturing hydroxyapatite (HAP), tricalcium phosphate (TCP), and other calcium-based products. The company's activities are focussed on synthetic bone graft substitutes, sustained-release drug delivery devices, and applications of HAP for protein purification. The company's catalog offers a large variety of products with tailored morphologies and microstructures to match their needs for orthopedic surgery, bone tissue engineering, and life science research. Cem-Ostetic and Bi-Ostetic bone void fillers are approved for sale in the USA and the European Community.
EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
NanoPass Technologies develops and commercializes painless intradermal (skin) delivery solutions for vaccines and large molecules. NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.